ZA200507638B - Acylated spiropiperidine derivatives as melanocortin-4 receptor agonists - Google Patents

Acylated spiropiperidine derivatives as melanocortin-4 receptor agonists

Info

Publication number
ZA200507638B
ZA200507638B ZA200507638A ZA200507638A ZA200507638B ZA 200507638 B ZA200507638 B ZA 200507638B ZA 200507638 A ZA200507638 A ZA 200507638A ZA 200507638 A ZA200507638 A ZA 200507638A ZA 200507638 B ZA200507638 B ZA 200507638B
Authority
ZA
South Africa
Prior art keywords
melanocortin
receptor agonists
spiropiperidine derivatives
acylated spiropiperidine
acylated
Prior art date
Application number
ZA200507638A
Other languages
English (en)
Inventor
Liangqin J T Guo
Jian S I K Liu
Zhixioing Ye
Shuwen He
Yingjie Lai
Ravi P Nargund
Feroze Ujjainwalla
Jonathan R Young
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of ZA200507638B publication Critical patent/ZA200507638B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/20—Spiro-condensed ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA200507638A 2003-04-04 2005-09-21 Acylated spiropiperidine derivatives as melanocortin-4 receptor agonists ZA200507638B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US46029303P 2003-04-04 2003-04-04

Publications (1)

Publication Number Publication Date
ZA200507638B true ZA200507638B (en) 2006-08-30

Family

ID=33159758

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200507638A ZA200507638B (en) 2003-04-04 2005-09-21 Acylated spiropiperidine derivatives as melanocortin-4 receptor agonists

Country Status (17)

Country Link
US (1) US7329673B2 (ja)
EP (1) EP1613601A4 (ja)
JP (1) JP3856815B2 (ja)
KR (1) KR20050120773A (ja)
CN (2) CN1768041A (ja)
AU (1) AU2004227835B2 (ja)
BR (1) BRPI0409078A (ja)
CA (1) CA2520114A1 (ja)
EC (1) ECSP056073A (ja)
HR (1) HRP20050876A2 (ja)
IS (1) IS8039A (ja)
MA (1) MA27752A1 (ja)
MX (1) MXPA05010724A (ja)
NO (1) NO20055166L (ja)
RU (1) RU2005134230A (ja)
WO (1) WO2004089307A2 (ja)
ZA (1) ZA200507638B (ja)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6374762B1 (en) * 1997-10-27 2002-04-23 Correct Craft, Inc. Water sport towing apparatus
KR20050120773A (ko) * 2003-04-04 2005-12-23 머크 앤드 캄파니 인코포레이티드 멜라노코르틴-4 수용체 작용제로서의 아실화스피로피페리딘 유도체
US7786141B2 (en) * 2004-08-19 2010-08-31 Vertex Pharmaceuticals Incorporated Dihydrospiroindene modulators of muscarinic receptors
MX2007002033A (es) * 2004-08-19 2007-04-26 Vertex Pharma Moduladores de receptores muscarinicos.
MX2007005820A (es) * 2004-11-18 2007-07-18 Incyte Corp Inhibidores de deshidrogenasa esteroide hidroxilo 11-beta tipo 1 y metodos de uso de los mismos.
NZ555444A (en) * 2004-11-29 2011-01-28 Vertex Pharma Modulators of muscarinic receptors
GB0504556D0 (en) * 2005-03-04 2005-04-13 Pfizer Ltd Novel pharmaceuticals
AU2006297443B2 (en) * 2005-09-29 2010-08-12 Merck Sharp & Dohme Corp. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
AU2006304305B2 (en) * 2005-10-18 2010-04-01 Merck Sharp & Dohme Corp. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
WO2007076070A2 (en) * 2005-12-22 2007-07-05 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
AU2007221220A1 (en) * 2006-02-22 2007-09-07 Vertex Pharmaceuticals Incorporated Spiro condensed piperidnes as modulators of muscarinic receptors
JP2009527568A (ja) * 2006-02-22 2009-07-30 バーテックス ファーマシューティカルズ インコーポレイテッド ムスカリン受容体の調節剤
US7858790B2 (en) * 2006-06-29 2010-12-28 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
WO2008021375A2 (en) * 2006-08-15 2008-02-21 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
JP2010501561A (ja) 2006-08-18 2010-01-21 バーテックス ファーマシューティカルズ インコーポレイテッド ムスカリン受容体の調節剤
EP2083831B1 (en) 2006-09-22 2013-12-25 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
JPWO2008038692A1 (ja) * 2006-09-28 2010-01-28 萬有製薬株式会社 ジアリールケチミン誘導体
AU2008233662B2 (en) 2007-04-02 2012-08-23 Msd K.K. Indoledione derivative
MX2010003373A (es) * 2007-10-03 2010-04-30 Vertex Pharma Moduladores de receptores muscarinicos.
US20090131465A1 (en) * 2007-10-30 2009-05-21 Chen Alex M Synthesis and crystalline forms of melanocortin-4 receptor agonist
JP2011504499A (ja) * 2007-11-21 2011-02-10 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ トリプターゼ阻害剤として使用するためのスピロピペリジン
WO2010037081A1 (en) * 2008-09-29 2010-04-01 Palatin Technologies, Inc. Melanocortin receptor-specific spiro-piperidine compounds
EP2358200A4 (en) 2008-11-17 2012-05-16 Merck Sharp & Dohme BICYCLIC AMINES SUBSTITUTED FOR THE TREATMENT OF DIABETES
EP2403337A4 (en) * 2009-03-03 2012-08-15 Univ Vanderbilt ALKYLSULFONYL-2,3-DIHYDROSPIRO [INDEN-1,4'-PIPERIDIN] ANALOGUE AS A GLYT1 INHIBITOR, METHOD FOR THE PRODUCTION THEREOF, AND ITS USE IN THE TREATMENT OF PSYCHIATRIC ILLNESSES
US20120220567A1 (en) 2009-07-23 2012-08-30 Shipps Jr Gerald W Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
WO2011011506A1 (en) 2009-07-23 2011-01-27 Schering Corporation Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
AR078522A1 (es) * 2009-10-15 2011-11-16 Lilly Co Eli Compuesto de espiropiperidina, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para tratar diabetes y compuesto intermediario para su sintesis
AR078948A1 (es) * 2009-11-30 2011-12-14 Lilly Co Eli Compuestos de espiropiperidina, composicion farmaceutica que lo comprenden y su uso para preparar un medicamento util para tratar la diabetes
WO2011137024A1 (en) 2010-04-26 2011-11-03 Merck Sharp & Dohme Corp. Novel spiropiperidine prolylcarboxypeptidase inhibitors
US9365539B2 (en) 2010-05-11 2016-06-14 Merck Sharp & Dohme Corp. Prolylcarboxypeptidase inhibitors
US9006268B2 (en) 2010-06-11 2015-04-14 Merck Sharp & Dohme Corp. Prolylcarboxypeptidase inhibitors
CN102659675A (zh) * 2011-12-27 2012-09-12 盛世泰科生物医药技术(苏州)有限公司 6-溴-2-甲基磺酰基-1,2,3,4,-四氢异喹啉的一种合成方法
JP6990657B2 (ja) * 2016-02-08 2022-01-13 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｄｄｒ１阻害剤としてのスピロインドリノン
TW202140480A (zh) * 2020-01-15 2021-11-01 日商拉夸里亞創藥股份有限公司 作為crhr2拮抗劑之螺雜環衍生物
WO2024175928A1 (en) * 2023-02-23 2024-08-29 Omass Therapeutics Limited Mc2r modulator compounds

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL96507A0 (en) 1989-12-08 1991-08-16 Merck & Co Inc Nitrogen-containing spirocycles and pharmaceutical compositions containing them
CA2037287A1 (en) 1990-03-02 1991-09-03 Ben E. Evans Spirocyclic oxytocin antagonists
EP0444945A3 (en) 1990-03-02 1992-05-13 Merck & Co. Inc. Use of spirocyclic compounds as oxytocin antagonists
CA2143117A1 (en) 1992-10-07 1994-04-14 Ben E. Evans Tocolytic oxytocin receptor antagonists
US5464788A (en) 1994-03-24 1995-11-07 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
GB9601724D0 (en) 1996-01-29 1996-03-27 Merck Sharp & Dohme Therapeutic agents
US5804578A (en) 1996-04-03 1998-09-08 Merck & Co., Inc. Piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
US6166037A (en) 1997-08-28 2000-12-26 Merck & Co., Inc. Pyrrolidine and piperidine modulators of chemokine receptor activity
EP1085869A4 (en) 1998-06-11 2001-10-04 Merck & Co Inc SPIRO PIPERID DERIVATIVES AS MELANOCORTIN RECEPTORAGONISTS
US6294534B1 (en) * 1998-06-11 2001-09-25 Merck & Co., Inc. Spiropiperidine derivatives as melanocortin receptor agonists
AU4562799A (en) 1998-06-15 2000-01-05 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
WO2000051607A1 (en) 1999-03-02 2000-09-08 Merck & Co., Inc. 3-cyclopropyl and 3-cyclobutyl pyrrolidine modulators of chemokine receptor activity
US6303593B1 (en) 1999-03-02 2001-10-16 Merck & Co., Inc. 3-thienyl and 3-furanyl pyrrolidine modulators of chemokine receptor activity
WO2001070337A1 (en) 2000-03-23 2001-09-27 Merck & Co., Inc. Spiropiperidine derivatives as melanocortin receptor agonists
US7015235B2 (en) 2001-02-28 2006-03-21 Merck & Co., Inc. Acylated piperidine derivatives as melanocortin-4 receptor agonists
ATE430565T1 (de) 2001-02-28 2009-05-15 Merck & Co Inc Acylierte piperidinderivate als melanocortin-4- rezeptoragonisten
ATE413175T1 (de) 2001-04-18 2008-11-15 Euro Celtique Sa Spiroinden- und spiroindan-verbindungen
US20030078278A1 (en) 2001-06-26 2003-04-24 Pfizer Inc. Spiropiperidine compounds as ligands for ORL-1 receptor
WO2004069798A1 (ja) 2003-02-10 2004-08-19 Banyu Pharmaceutical Co.,Ltd. ピペリジン誘導体を有効成分とするメラニン凝集ホルモン受容体拮抗剤
EP1468999A1 (en) 2003-03-20 2004-10-20 MyoContract Ltd. Substituted piperidine and piperazine derivatives as melanocortin-4 receptor modulators
EP1460073A1 (en) 2003-03-20 2004-09-22 MyoContract Ltd. Substituted piperidine and piperazine derivatives as melanocortin-4 receptor modulators
KR20050120773A (ko) * 2003-04-04 2005-12-23 머크 앤드 캄파니 인코포레이티드 멜라노코르틴-4 수용체 작용제로서의 아실화스피로피페리딘 유도체
CA2540197A1 (en) 2003-09-26 2005-04-07 Pfizer Products Inc. Treatment of neurological disorders related to rapid eye movement (rem) sleep disturbances with npy y5 receptor antagonists
JP2007510662A (ja) 2003-11-04 2007-04-26 エリクシアー ファーマシューティカルズ， インコーポレイテッド 治療化合物およびその使用

Also Published As

Publication number Publication date
JP3856815B2 (ja) 2006-12-13
NO20055166D0 (no) 2005-11-03
WO2004089307A8 (en) 2005-06-23
AU2004227835A1 (en) 2004-10-21
KR20050120773A (ko) 2005-12-23
US20060183904A1 (en) 2006-08-17
MXPA05010724A (es) 2005-12-15
IS8039A (is) 2005-09-22
CA2520114A1 (en) 2004-10-21
JP2006522132A (ja) 2006-09-28
CN101108825A (zh) 2008-01-23
AU2004227835B2 (en) 2007-06-14
EP1613601A2 (en) 2006-01-11
HRP20050876A2 (en) 2006-06-30
RU2005134230A (ru) 2006-05-10
US7329673B2 (en) 2008-02-12
MA27752A1 (fr) 2006-02-01
WO2004089307A2 (en) 2004-10-21
EP1613601A4 (en) 2007-05-02
CN1768041A (zh) 2006-05-03
WO2004089307A3 (en) 2005-03-31
BRPI0409078A (pt) 2006-04-18
ECSP056073A (es) 2006-03-01
NO20055166L (no) 2005-12-30

Similar Documents

Publication Publication Date Title
ZA200507638B (en) Acylated spiropiperidine derivatives as melanocortin-4 receptor agonists
IL190282A0 (en) Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
IL174953A0 (en) Dihydrobenzofuranyl alkanamine derivatives as 5ht2c agonists
GB0424676D0 (en) Holder for elongated objects
IL169905A0 (en) Novel 2-pyridinecarboxamide derivatives
IL196021A0 (en) Pyrazolopyridine derivatives uses
EP1940401A4 (en) ACYLATED SPIROPIPERIDINE DERIVATIVES AS MODIFIERS TO MELANOCORTIN-4 RECEPTOR
ZA200703674B (en) Acylated nonadepsipeptides used as lysobactin derivatives
HK1066269A1 (en) Adjustable probe
EP1643987A4 (en) PODOPHYLLOTOXIN DERIVATIVES
PT1625153E (pt) Nonadepsipéptidos acilados do tipo lisobactina
EP1634529A4 (en) HOLDER
HK1066271A1 (en) Adjustable probe
GB2401183B (en) Probe
EP1694330A4 (en) DERIVATIVES OF VINORELBINE
EP1773347A4 (en) PIPERIDINE ACYLATED DERIVATIVES AS MELANOCORTIN RECEPTOR AGONISTS 4
HK1066270A1 (en) Adjustable probe
GB0426050D0 (en) Cable holder
GB0312368D0 (en) Novel ureido- and amido-pyrazolone derivatives
ZA200802989B (en) Naphthyridin derivatives
GB0323573D0 (en) Improved probe
IL156789A0 (en) Adapter for multi-element contact-probe
GB0315629D0 (en) New uses for antibiotic
GB2415431B (en) Thionucleoside S-nitrosyl derivatives
EP1623953A4 (en) PROBE